Drugs / Digoxin Antibodies Fab Fragments
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03810417 Comparator | Jul 2019 → Apr 2024 | acute kidney injury | University of Maryland, Baltimore | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Digoxin Antibodies Fab Fragments | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03810417 ↗ |
| Known as | DigiFab | “a medication called DigiFab to lower the ouabain levels” NCT03810417 ↗ |
| Modality | Protein / enzyme biologic | “Digoxin antibodies” NCT03810417 ↗ |
| Route | Intravenous | “Digifab intravenous in subject with baseline ouabain concentration \> 360 pm” NCT03810417 ↗ |